长春高新(000661.SZ)：子公司注射用GenSci136境内生产药品注册临床试验申请获得受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of its injectable GenSci136, a first-class therapeutic biological product developed in-house, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - Jinsai Pharmaceutical's injectable GenSci136 is a first-class therapeutic biological product developed for the treatment of IgAN [1] - GenSci136 is a B-cell maturation antigen (BCMA) trimeric fusion protein that can bind to B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL) [1] - The drug has the potential to treat various autoimmune diseases characterized by tissue damage caused by pathogenic antibodies, by affecting the survival and differentiation of B lymphocytes and plasma cells [1]